Blawg Search - Law Blogs, Lawyer Blogs, Legal Blogs Directory & Search Engine

... in Peapack, New Jersey. (Am. Compl. 9). In April 2003, Pharmacia was acquired by Pfizer, Inc. (Am. Compl. 10). Rost alleges that beginning in 1997, and continuing to ... , after nearly three years of investigation, the government declined to intervene in the case. Id. Pfizer moved to dismiss Dr. Rost's complaint for lack of subject matter jurisdiction under ... need not consider "bald assertions [or] unsupportable conclusions." Doyle v. Hasbro, Inc., 103 F.3 186, 190 (1st Cir. 1996) (citation omitted). ...

... of changes and turmoil over the last few months. First Alan Hesketh, Pfizer Inc.'s vice president and global head of patents was charged with child pornography ... I set out to find out if those rumors had surfaced outside Pfizer. And lo and behold, turns out those allegations had already ... a complete erosion of trust in senior management. So in that context these allegations inside Pfizer are informative. And the fact that the legal department is in this situation is even more noteworthy, considering ...

By Donald Zuhn -- On Monday, the Federal Circuit denied a combined petition for panel rehearing and rehearing en banc filed by Plaintiff-Appellee Pfizer, Inc. The Federal Circuit's denial of Pfizer's petition for rehearing en banc was not unanimous, with Judges Newman, Lourie, and Rader each writing their own dissent....

Pharmaceutical giant, Pfizer Inc, will disclose its compensation paid to U.S. healthcare professionals for consulting, speaking engagements and clinical trials. The disclosure will include payments made to practicing U.S. physicians and other healthcare providers, as well as principal investigators, major academic institutions and research sites for clinical research. This makes Pfizer the first biopharmaceutical company to [...]

On October 31, 2008, the Supreme Court gave itself an extension of time, through December 4, 2008, to grant or deny review in Clayworth v. Pfizer, Inc., no. S166435. Clayworth is an interesting case that I did not have time...

The Supreme Court has posted its statement of issues on review in Clayworth v. Pfizer, Inc., no. S166435. The UCL-related issues are particularly interesting: (1) When plaintiffs pay overcharges on goods or services as a result of the anticompetitive conduct...

By Kevin E. Noonan -- On Friday, the Court of Appeals for the Federal Circuit handed Pfizer a mixed decision on defendant Teva's appeal of a District Court judgment that Teva was liable for infringing a trio of Pfizer patents (U.S. Patent Nos. 5,466,823; 5,563,165; and 5,760,068) relating to the...

By Donald Zuhn --- In an appeal from a District Court judgment of validity, enforceability, and infringement, the Federal Circuit reversed the District Court's finding of validity, holding that U.S. Patent No. 4,879,303 (the '303 patent) was rendered obvious by, inter alia, U.S. Patent No. 4,572,909 (the '909 patent) and...

... waived by private agreement without judicial or governmental supervision. 5. Release of claims by Pfizer. a. In consideration of and in exchange for Dr. Goodman's acceptance of this Agreement and the obligations ... PH.D. /s/ Corey S. Goodman Dated: April 27, 2009. PFIZER INC By: /s/ Amy W. Schulman Amy W. Schulman, Senior Vice ... 25, 2009 (the "Agreement"), including but not necessarily limited to the acceptance by Pfizer Inc ("Pfizer") of my resignation effective May 31, 2009 (my "Resignation Date ...

... Shannon Pettypiece, Tom Randall and Zachary Mider Jan. 25 (Bloomberg) -- Pfizer Inc. would pay about $66.8 billion to acquire Wyeth in a bid being reviewed ... Promise and Peril The Wyeth transaction carries both promise and peril for Pfizer, analysts and investors said in interviews since talks were first reported ... over the previous five years. McKinnell, while being groomed as CEO in 2001, was instrumental in Pfizer's $115 billion acquisition of Warner- Lambert Co., the developer of Lipitor. After ...